Nevin Abernethy - Anteo Diagnostics Insider

Anteo Diagnostics Limited -- Australia Stock  

AUD 0.02  0.01  33.33%

Chief Product Development and Research Officer

Dr. Nevin Abernethy Ph.D. is Chief Product Development and Research Officer of Anteo Diagnostics Limited. He was awarded his PhD in animal physiology by the University of Toronto Canada in 1989. After working as a Research Officer and lecturer at the University of Melbournes Department of Veterinary and PreClinical Sciences he moved to Auckland New Zealand where he was a Research Fellow in the Department of Molecular Medicine at the University of Auckland prior to joining Genesis Research and Development Corporationration at the time the biotech company in New Zealand. Nevin is named as an inventor on a number of patents in the area of therapeutics and immunological diseases has published numerous peer reviewed papers in related areas and has demonstrated in product development programs similar to those of interest to BioLayer.
  Executive Since 2007      
61 7 3219 0085  http://www.anteodx.com

Management Efficiency

The company has return on total asset (ROA) of (2.76) % which means that it has lost $2.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (45.51) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Anteo Diagnostics Limited, a medical technology company, develops and commercializes specialized surfaces for use in life sciences industries in Australia. Anteo Diagnostics Limited (ADO) is traded on Australian Securities Exchange in Australia. It is located in Eight Mile Plains, QLD and employs 99 people.

Did you try this?

Run Risk-Return Analysis Now
   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
Hide  View All  Next  Launch Risk-Return Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Anteo Diagnostics Limited to your portfolio

Top Management

Anteo Diagnostics Limited Leadership Team
Nobuyoshi Maeji, Executive, Ph.D
Alan Studley, Director, CPA
Mark Bouris, Chairman
Peter HardingSmith, CFO
John Hurrell, Director, Ph.D
Geoffrey Cumming, CEO
Tamara Mills, COO
Julien McInally, Executive, CPA
Shane Hartwig, Executive
Nevin Abernethy, Executive
Richard Martin, Director
Jef Vangenechten, CEO, Ph.D
Rolf Sickman, Director
Sandra Andersen, Director, CPA

Stock Performance

Anteo Diagnostics Performance Indicators